NASDAQ · Medical - Instruments & Supplies

NYXH (NYXH) Stock

$1.41 -2.76% NASDAQ: NYXH Healthcare

Valuation

MetricValue
Price$1.41
Market Cap$55.85M
P/E Ratio-1.23
P/B Ratio2.23
P/S Ratio6.06
EPS (TTM)$-2.37
52-Week High$8.59
52-Week Low$1.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-183.67%
ROA-76.27%
ROCE-169.39%
Gross Margin-830.00%
Operating Margin-830.00%
Net Margin-5.28%
Debt/Equity1.01
Current Ratio1.24

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$3.0M$4.0M$5.0M$10.0M
Operating Profit$-26.0M$-32.0M$-45.0M$-59.0M$-83.0M
Net Profit$-28.0M$-31.0M$-43.0M$-59.0M$-90.0M
EPS$-1.16$-1.21$-1.55$-1.81$-2.37
Op Margin-3080.1%-1053.8%-1037.3%-1300.8%-827.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$171.0M$146.0M$124.0M$158.0M$118.0M
Total Liabilities$22.0M$26.0M$26.0M$45.0M$69.0M
Cash$136.0M$18.0M$22.0M$34.0M$30.0M
Borrowings$12.0M$12.0M$13.0M$23.0M$42.0M

Latest News

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day MarketBeat · Jul 10, 2026 Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst Caution Simply Wall St. · Jul 8, 2026 Nyxoah Preliminary Q2 Revenue Rises From Q1; 2026 Outlook Reaffirmed MT Newswires · Jul 7, 2026 Nyxoah Announces Preliminary Results for the Second Quarter of 2026 GlobeNewswire · Jul 7, 2026 Information on the total number of voting rights and shares GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-25.0M$-29.0M$-45.0M$-49.0M$-67.0M
Investing Cash Flow$-24.0M$-106.0M$21.0M$-22.0M$25.0M
Financing Cash Flow$0$0$0$-1.0M$-3.0M
Net Cash Flow$43.0M$-118.0M$4.0M$13.0M$0
Free Cash Flow$-37.0M$-45.0M$-56.0M$-55.0M$-68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-74.12%
Quick Ratio0.88
Interest Coverage-41.50
Return 1Y-80.08%
Return 3Y-78.88%
Return 5Y-95.32%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATX $3.00 +1.01% -2.59 $342.14M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%
IVVD $0.55 +3.10% -3.53 $162.51M 0.00%
KRMD $4.11 +0.00% -67.33 $188.78M 0.00%
OABI $2.00 +2.04% -3.84 $238.18M 0.00%

About NYXH

NYXH is led by CEO Olivier Taelman, publicly traded since 2021.

NYXH stock trades at $1.41 with a market capitalization of $55.85M. The stock is valued at a price-to-earnings (P/E) ratio of -1.23, price-to-book of 2.23, price-to-sales of 6.06. Over the past 52 weeks the stock has ranged between $1.26 and $8.59, and currently trades 83.6% below its 52-week high.

On profitability, NYXH generates a return on equity (ROE) of -183.67%, return on capital employed of -169.39%, an operating margin of -830.00%, a net profit margin of -5.28%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides